相关实验视频

Updated: Jul 1, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

放射性核素标记的抗沉声功能1a抑制酸用于瘤识别和个性化治疗

Xiumin Shi^1,2, Teng Liu¹, Pei Pei¹

¹State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Suzhou Medical College, Soochow University, Suzhou, Jiangsu 215123, China.

|March 13, 2024

概括

抗沉声功能1a (ASF1a) 作为免疫PET (iPET) 成像的生物标志物,用于预测抗PD-1治疗反应. 高的ASF1a水平表明耐药性,指导个性化组合或α粒子治疗以改善结果.

科学领域:

在瘤学瘤学.
核医学是一种核医学.
免疫治疗是一种免疫疗法.

背景情况:

免疫检查点阻塞 (ICB) 疗法在癌症治疗中表现有前途,但受到了低响应率和患者分层不良的影响.
非侵入性正子发射断层扫描 (PET) 成像,结合特定的免疫生物标志物,可以为指导癌症治疗提供时空洞察力.

研究的目的:

通过使用免疫PET (iPET) 来识别抗沉默功能1a (ASF1a) 作为一种用于划分瘤免疫微环境的新型生物标志物.
开发一种针对ASF1a的iPET放射追踪器,用于预测抗PD-1 (αPD-1) 治疗反应.
探索基于ASF1a iPET成像的ICB抗性瘤的治疗策略.

主要方法:

开发一种针对ASF1a的iPET放射追踪器 (Ga-AP1).
iPET 信号强度与抗PD-1 治疗反应的相关性.
对ICB耐药瘤的组合疗法 (Lu-AP1和αPD-1) 和α粒子疗法 (Ac-AP1) 的评估.

主要成果:

在瘤中,Ga-AP1 iPET 追踪器成功准了ASF1a.
iPET信号强度与抗PD-1治疗反应呈负相关性,识别了ICB耐药瘤 (ASF1a^高iPET).
组合疗法和独立的Ac-AP1疗法在ICB耐药模型中显著提高了疗效和延长了存活时间.

结论:

ASF1a是iPET成像的可行的生物标志物,用于评估瘤免疫微环境并预测ICB反应.
开发的放射追踪器为评估免疫反应和分层免疫治疗患者提供了一个工具.
多功能放射性核素标记AP1为ICB耐药癌症提供了潜在的治疗策略,使同时诊断和个性化治疗计划成为可能.

关键词:

在ASF1a中,我们可以使用ASF1a.在ICB治疗中,ICB疗法是指ICB治疗.在 iPET 中,您可以使用 iPET.放射性核化物放射性核化物一个α粒子疗法.

更多相关视频

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...